RxDoctor Payments Data

Jennifer Fisher

Surgical · Farmington, CTNPI 1407543945

Payments from drug & device makers

$1,011in general payments, 2019–2025

Across 19 payments — averaging $53.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$379
  • LEO Pharma Inc.$176
  • Novo Nordisk$166
  • Tandem Diabetes Care, Inc.$152
  • Amgen$45
  • BETA Bionics, Inc.$44
  • plus $50 from 2 others

What the payments were for

  • Food & beverage$1,011100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,011 in reported general payments places this provider in the 75th percentile of 568 surgical providers in Connecticut.

See all surgical providers in Connecticut

Medicare billing

Part B allowed, 2024
$25,211
Medicare patients
109
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide200$265,938
MounjaroTirzepatide129$162,761
JardianceEmpagliflozin45$70,361
TrulicityDulaglutide37$53,488
FarxigaDapagliflozin Propanediol21$33,232
Tresiba Flextouch U-100Insulin Degludec36$24,029
RybelsusSemaglutide14$21,520
BaqsimiGlucagon25$13,063
Novolog FlexpenInsulin Aspart40$11,514
Insulin Lispro Kwikpen U-100Insulin Lispro27$10,914
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$9,326
VascepaIcosapent Ethyl16$7,385
Humalog Kwikpen U-100Insulin Lispro26$6,640
Nano 2nd Gen Pen NeedlePen Needle, Diabetic33$4,416
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic18$2,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$166$287,458214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 568 surgical providers in Connecticut.

Other surgical in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →